

**Reference:** FOI.ICB-2526/129

**Subject:** Continence and Stoma Care Formularies

*I can confirm that the ICB does hold the information requested; please see responses below:*

QUESTION	RESPONSE
<p>1. Does your organisation have an active Ostomy (stoma) or Continence Care Formulary? If so, please share copies of both formularies, including the full list of products?</p>	<p>Yes, please see our Remedy website, here: <a href="https://remedy.bnssg.icb.nhs.uk/formulary-adult/local-guidelines/20-appliances-and-part-ix/">https://remedy.bnssg.icb.nhs.uk/formulary-adult/local-guidelines/20-appliances-and-part-ix/</a></p>
<p>2. What NHS organisations are they applicable to?</p>	<p>All acute trusts, GP practices and Sirona care &amp; health within the BNSSG area.</p>
<p>3. When was the formulary start date, and when will it end or is expected to be renewed?</p>	<p>Existing formularies: <b>Stoma</b> – Start date June 2024, review date June 2027. <b>Urology appliances</b> – Start date Apr 2025, review date April 2028.</p>
<p>4. What is the primary objective of the formulary? If this is to deliver cost-improvement/savings, please quantify what savings the formulary has delivered to your organisation each year since it was active?</p>	<p>To optimise the use of products, provide highest possible quality of care to patients, improve patient outcomes and ensure financial sustainability.</p>

<p>5. Which part of your organisation benefits from any Formulary savings?</p>	<p>Savings are made across the BNSSG (Bristol, North Somerset and South Gloucestershire) integrated care system in.</p>
<p>6. What is the process for renewal?</p>	<p>Medicines Optimisation team will automatically initiate the renewal process 3 months before the review date of the existing formulary. The team will liaise with specialist healthcare providers and healthcare professionals to review current prescribing and products available in the Drug Tariff. Specialists will appraise products and glean views of patients before deciding on formulary inclusion.</p>
<p>7. Where new, innovative products are launched while the formulary is live, what is the process for reviewing these and adding to the formulary?</p>	<p>Email new product information to: <a href="mailto:bnssg.medicines-optimisation@nhs.net">bnssg.medicines-optimisation@nhs.net</a></p> <p>The Medicines Optimisation team will then review the product with local specialist healthcare providers and healthcare professionals and decide whether to make a formulary amendment.</p>
<p>8. Other than cost, how are outcomes measured and which outcomes are measured when assessing the effectiveness of the formulary?</p>	<ul style="list-style-type: none"> <li>• Hospital attendance and admissions monitored quarterly</li> <li>• Prescribing data analysed for trends quarterly</li> <li>• Patient outcomes are reviewed by the healthcare professional based on their individual care</li> </ul>
<p>9. Are stoma bags included within your formularies?</p>	<p>Yes.</p>
<p>10. Who are the lead clinical stakeholder(s) responsible for the formularies – name and job role please?</p>	<p>The Medicines Optimisation team: <a href="mailto:bnssg.medicines-optimisation@nhs.net">bnssg.medicines-optimisation@nhs.net</a></p>

<p>11. Who are the lead nonclinical stakeholder(s) responsible for the formularies – name and job role please?</p>	<p>None – all stakeholders are clinicians/healthcare professionals.</p>
<p>12. How is formulary compliance measured by healthcare professionals in your organisation?</p>	<p>Prescribing data is analysed quarterly.</p>

***The information provided in this response is accurate as of 11 August 2025 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.***